LMAN2L

Across TCGA pan-cancer cohorts, LMAN2L mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LMAN2L data layer compared with 21 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher LMAN2L mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated LMAN2L expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where LMAN2L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	IV	0.451	1.000	.016	19	view →
PDAC	OS	Tertile	IV	0.973	0.443	.024	9	view →
LSCC	OS	Quartile	III,IV	0.527	0.928	.023	6	view →
HNSC	OS	Quartile	IV	0.895	0.675	.029	2	view →
UCEC	DFS	Quartile	All	0.875	1.000	.048	2	view →
LUAD	OS	Median	III,IV	0.634	0.221	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LMAN2L–CCRCC (OS)

Open the CCRCC breakdown →